# 2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML

> **NCT04953780** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **West Virginia University** · enrollment: 6 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Calaspargase pegol-mknl

## Key facts

- **NCT ID:** NCT04953780
- **Lead sponsor:** West Virginia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-09-27
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04953780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04953780, "2157GCCC:Phase 1 of Calaspargase Pegol-mknl W/ Cytarabine and Idarubicin in Newly Dx AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04953780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*